Research programme: stem cell-based therapeutics - ViaCyte

Drug Profile

Research programme: stem cell-based therapeutics - ViaCyte

Alternative Names: PEC-01™; Stem cell-derived pancreatic progenitor cells - ViaCyte

Latest Information Update: 12 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BetaLogics; ViaCyte Inc
  • Developer University of California at San Francisco; ViaCyte Inc
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements; Pancreatic beta cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Type 1 diabetes mellitus

Most Recent Events

  • 29 Mar 2017 ViaCyte and W. L. Gore & Associates collaborate to develop novel implantable delivery technologies for cell therapies
  • 03 Feb 2016 BetaLogics consolidated its assets into ViaCyte
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top